Deal Note: Crowell & Moring Client Integrated BioTherapeutics Enters Into Exclusive Agreement with Chembio Diagnostics to Develop POC Diagnostic Tests for Ebola
Firm News | less than 1 min read | 10.27.14
Washington, D.C. – October 27, 2014: Crowell & Moring, LLP is representing Integrated BioTherapeutics, Inc. (IBT), a biotechnology company focused on the discovery of novel vaccines and therapeutics for emerging infectious diseases, as it enters into an exclusive agreement with Chembio Diagnostics, Inc., a leader in point-of-care (POC) diagnostic tests for infectious diseases. Under the terms of the agreement, Chembio will combine its patented DPP technology with IBT's proprietary Ebola reagents to develop POC diagnostic tests for Ebola and febrile illness. Chembio will have exclusive rights to any POC product developed through this agreement. Financial terms of the agreement were not disclosed.
Insights
Firm News | 3 min read | 06.30.25
Former Microsoft Assistant General Counsel Scott Wise Joins Crowell & Moring
Denver – June 30, 2025: Scott Wise, most recently assistant general counsel for global trade at Microsoft, has joined Crowell & Moring as a partner in the firm’s International Trade Group.
Firm News | 2 min read | 06.26.25
Crowell & Moring Honors Recipients of 26th Annual George Bailey Public Service Awards
Firm News | 3 min read | 06.24.25
Senior DHS Cyber and Emerging Technology Official Matthew F. Ferraro Joins Crowell & Moring
Firm News | 1 min read | 06.20.25
Human Rights First Honors Rosa Morales with Pro Bono Star Award